{"id":"https://openalex.org/W7221662015","doi":"https://doi.org/10.3390/livers6050107","title":"Effects of SGLT2 Inhibitor Therapy Combined with a Moderate-Carbohydrate Diet in Patients with MASLD","display_name":"Effects of SGLT2 Inhibitor Therapy Combined with a Moderate-Carbohydrate Diet in Patients with MASLD","publication_year":2026,"publication_date":"2026-10-13","ids":{"openalex":"https://openalex.org/W7221662015","doi":"https://doi.org/10.3390/livers6050107"},"language":"en","primary_location":{"id":"doi:10.3390/livers6050107","doi":"https://doi.org/10.3390/livers6050107","is_oa":true,"landing_page_url":"https://doi.org/10.3390/livers6050107","pdf_url":null,"source":{"id":"https://openalex.org/S4210233479","display_name":"Livers","issn_l":"2673-4389","issn":["2673-4389"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Livers","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3390/livers6050107","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029428902","display_name":"Hideyuki Tamai","orcid":"https://orcid.org/0000-0003-4511-4573","observed_orcids":["https://orcid.org/0000-0003-4511-4573"]},"institutions":[{"id":"https://openalex.org/I4210090760","display_name":"Wakayama Rosai Hospital","ror":"https://ror.org/00awxvj03","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210090760"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hideyuki Tamai","raw_affiliation_strings":["Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 640-8505, Japan"],"raw_orcid":"https://orcid.org/0000-0003-4511-4573","affiliations":[{"raw_affiliation_string":"Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 640-8505, Japan","institution_ids":["https://openalex.org/I4210090760"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021225592","display_name":"Jumpei Okamura","orcid":"https://orcid.org/0000-0002-3312-4128","observed_orcids":["https://orcid.org/0000-0002-3312-4128"]},"institutions":[{"id":"https://openalex.org/I4210090760","display_name":"Wakayama Rosai Hospital","ror":"https://ror.org/00awxvj03","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210090760"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Jumpei Okamura","raw_affiliation_strings":["Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 640-8505, Japan"],"raw_orcid":"https://orcid.org/0000-0002-3312-4128","affiliations":[{"raw_affiliation_string":"Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 640-8505, Japan","institution_ids":["https://openalex.org/I4210090760"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5029428902"],"corresponding_institution_ids":["https://openalex.org/I4210090760"],"apc_list":{"value":1000,"currency":"CHF","value_usd":1207},"apc_paid":{"value":1000,"currency":"CHF","value_usd":1207},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.86309838,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"6","issue":"5","first_page":"107","last_page":"107"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.006300000008195639,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-alcoholic-fatty-liver-disease","display_name":"non-alcoholic fatty liver disease","score":0.9660000205039978},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/luseogliflozin","display_name":"luseogliflozin","score":0.9940000176429749},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7570000290870667},{"id":"https://openalex.org/keywords/liver-fat-reduction","display_name":"liver fat reduction","score":0.6759999990463257},{"id":"https://openalex.org/keywords/visceral-fat","display_name":"visceral fat","score":0.972000002861023},{"id":"https://openalex.org/keywords/alanine-aminotransferase-normalization","display_name":"alanine aminotransferase normalization","score":0.8069999814033508},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.765999972820282},{"id":"https://openalex.org/keywords/metabolic-parameters","display_name":"metabolic parameters","score":0.38600000739097595},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5090000033378601}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7297000288963318},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6527000069618225},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5455999970436096},{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.5394999980926514},{"id":"https://openalex.org/C2779881121","wikidata":"https://www.wikidata.org/wiki/Q105522","display_name":"Uric acid","level":2,"score":0.5116999745368958},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.4462999999523163},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.4442000091075897},{"id":"https://openalex.org/C2777538456","wikidata":"https://www.wikidata.org/wiki/Q311213","display_name":"Glycated hemoglobin","level":4,"score":0.3912999927997589},{"id":"https://openalex.org/C2778606649","wikidata":"https://www.wikidata.org/wiki/Q305481","display_name":"Alanine transaminase","level":2,"score":0.3797999918460846},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.37929999828338623},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.37860000133514404},{"id":"https://openalex.org/C2777075537","wikidata":"https://www.wikidata.org/wiki/Q929737","display_name":"Liver disease","level":2,"score":0.3684000074863434},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.367000013589859},{"id":"https://openalex.org/C2776637226","wikidata":"https://www.wikidata.org/wiki/Q6658207","display_name":"Liver injury","level":2,"score":0.35910001397132874},{"id":"https://openalex.org/C2992872382","wikidata":"https://www.wikidata.org/wiki/Q305481","display_name":"Alanine aminotransferase","level":2,"score":0.3571999967098236},{"id":"https://openalex.org/C147990577","wikidata":"https://www.wikidata.org/wiki/Q25790","display_name":"Glycation","level":3,"score":0.3553999960422516},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34790000319480896},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.3440999984741211},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.3386000096797943},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.3246000111103058},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.3192000091075897},{"id":"https://openalex.org/C70818257","wikidata":"https://www.wikidata.org/wiki/Q502671","display_name":"Metabolic control analysis","level":3,"score":0.31439998745918274},{"id":"https://openalex.org/C2778917026","wikidata":"https://www.wikidata.org/wiki/Q43041","display_name":"Hemoglobin","level":2,"score":0.3043000102043152},{"id":"https://openalex.org/C2779856020","wikidata":"https://www.wikidata.org/wiki/Q218642","display_name":"Alanine","level":3,"score":0.28610000014305115},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.28450000286102295},{"id":"https://openalex.org/C2778913445","wikidata":"https://www.wikidata.org/wiki/Q186319","display_name":"Triglyceride","level":3,"score":0.2741999924182892},{"id":"https://openalex.org/C2780559512","wikidata":"https://www.wikidata.org/wiki/Q605709","display_name":"Fibrosis","level":2,"score":0.2703000009059906},{"id":"https://openalex.org/C2779721657","wikidata":"https://www.wikidata.org/wiki/Q49970","display_name":"Hyperuricemia","level":3,"score":0.2662000060081482},{"id":"https://openalex.org/C2776954865","wikidata":"https://www.wikidata.org/wiki/Q1546498","display_name":"Nonalcoholic fatty liver disease","level":4,"score":0.26489999890327454},{"id":"https://openalex.org/C2777422806","wikidata":"https://www.wikidata.org/wiki/Q409898","display_name":"Dapagliflozin","level":4,"score":0.2623000144958496},{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.25839999318122864},{"id":"https://openalex.org/C3018667095","wikidata":"https://www.wikidata.org/wiki/Q3455903","display_name":"Glucose homeostasis","level":4,"score":0.2565999925136566}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3390/livers6050107","doi":"https://doi.org/10.3390/livers6050107","is_oa":true,"landing_page_url":"https://doi.org/10.3390/livers6050107","pdf_url":null,"source":{"id":"https://openalex.org/S4210233479","display_name":"Livers","issn_l":"2673-4389","issn":["2673-4389"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Livers","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.3390/livers6050107","doi":"https://doi.org/10.3390/livers6050107","is_oa":true,"landing_page_url":"https://doi.org/10.3390/livers6050107","pdf_url":null,"source":{"id":"https://openalex.org/S4210233479","display_name":"Livers","issn_l":"2673-4389","issn":["2673-4389"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Livers","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Background/Objectives:":[0],"Moderate":[1],"carbohydrate":[2],"diets":[3],"(MCD)":[4],"and":[5,16,65,94,130,184,220,223],"sodium":[6],"glucose":[7],"cotransporter":[8],"2":[9,163],"inhibitors":[10],"(SGLT2i)":[11],"both":[12],"improve":[13],"metabolic":[14,20,172,225],"status":[15],"liver":[17,23,131,156,207,221],"injury":[18,208],"in":[19,116,124,155,170,188,206,217],"dysfunction-associated":[21],"steatotic":[22],"disease":[24],"(MASLD),":[25],"but":[26],"the":[27,62,74,117,189],"therapeutic":[28],"effect":[29],"of":[30],"their":[31],"combined":[32],"use":[33],"remains":[34],"unclear.":[35],"This":[36],"study":[37],"evaluated":[38],"whether":[39],"adding":[40,194],"an":[41,44,195,198],"SGLT2i":[42,196,233],"to":[43,61,73,197,240],"MCD":[45,57,199,241],"provides":[46],"incremental":[47],"benefit.":[48],"Methods:":[49],"Among":[50],"327":[51],"patients":[52,100],"with":[53,137],"MASLD,":[54],"259":[55],"receiving":[56,67],"alone":[58],"were":[59,71,134,143,153],"assigned":[60,72],"control":[63],"group,":[64],"68":[66],"luseogliflozin":[68],"2.5":[69],"mg/day":[70],"combination":[75,118,138,190],"group.":[76,102,191],"Propensity":[77],"score":[78],"matching":[79],"using":[80],"age,":[81],"sex,":[82],"height,":[83],"weight,":[84],"body":[85,125],"mass":[86],"index,":[87],"alanine":[88],"aminotransferase":[89],"(ALT),":[90],"hemoglobin":[91],"A1c":[92],"(HbA1c),":[93],"fibrosis-4":[95],"index":[96],"identified":[97],"53":[98],"matched":[99],"per":[101],"Results:":[103],"The":[104],"proportion":[105],"achieving":[106],"\u22657%":[107],"weight":[108,231],"loss":[109],"after":[110],"1":[111],"year":[112],"was":[113],"significantly":[114],"higher":[115],"group":[119,151],"(74%":[120],"vs.":[121,146],"26%).":[122],"Reductions":[123],"fat,":[126],"visceral":[127],"fat":[128,132,222],"area,":[129],"content":[133],"also":[135],"greater":[136,215],"therapy.":[139],"ALT":[140],"normalization":[141],"rates":[142],"similar":[144],"(64%":[145],"55%).":[147],"No":[148],"significant":[149],"between":[150],"differences":[152],"observed":[154],"enzymes,":[157],"shear":[158],"wave":[159],"velocity,":[160],"or":[161,209],"Mac":[162],"binding":[164],"protein":[165],"glycosylation":[166],"isomer":[167],"levels.":[168],"Improvements":[169],"several":[171],"parameters\u2014including":[173],"triglycerides,":[174],"uric":[175],"acid,":[176],"ferritin,":[177],"homeostatic":[178],"model":[179],"assessment":[180],"for":[181,242],"insulin":[182],"resistance,":[183],"HbA1c\u2014were":[185],"more":[186],"pronounced":[187],"Conclusions:":[192],"Although":[193],"did":[200],"not":[201],"provide":[202],"additional":[203],"short-term":[204],"benefits":[205],"fibrosis":[210],"markers,":[211],"it":[212],"produced":[213],"substantially":[214],"reductions":[216],"body,":[218],"visceral,":[219],"broader":[224],"improvements.":[226],"By":[227],"facilitating":[228],"clinically":[229],"meaningful":[230],"loss,":[232],"may":[234],"serve":[235],"as":[236],"a":[237],"valuable":[238],"adjunct":[239],"MASLD.":[243]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2026-10-14T00:00:00"}